View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 18, 2020updated 11 Jul 2022 9:52am

Sinovac’s CoronaVac triggers quick immune response in Covid-19 trial

Sinovac Biotech has reported the preliminary results from Phase I/II trial that showed its experimental Covid-19 vaccine, CoronaVac, triggered a quick immune response in healthy adults.

Sinovac Biotech has reported the preliminary results from Phase I/II trial that showed its experimental Covid-19 vaccine, CoronaVac, triggered a quick immune response in healthy adults.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Even though the early to mid-stage trials were not designed to evaluate the efficacy of the vaccine candidate, it could provide sufficient protection, researchers said.

Trial data showed that CoronaVac produced lower antibodies than in people who had recovered from Covid-19.

The randomised, double-blind, placebo-controlled trial enrolled over 700 healthy adults aged between 18 and 59 years in China.

The study findings were published in a peer-reviewed paper in The Lancet Infectious Diseases journal, Reuters reported.

One of the paper authors Zhu Fengcai told the news agency: “Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation by giving two doses of the vaccine at a 14-day interval.

“We believe that this makes the vaccine suitable for emergency use during the pandemic.”

CoronaVac is one of three experimental Covid-19 vaccines China has been using to inoculate hundreds of thousands of people under an emergency use programme.

The two other vaccines in the programme, both developed by institutes linked to Sinopharm, and another one from CanSino Biologics, were also shown to be safe.

Peer-reviewed papers showed that they also triggered immune responses in early and mid-stage trials.

Three Phase III trials of Sinovac’s vaccine candidate are currently progressing in Indonesia, Brazil and Turkey.

According to the researchers, findings from large, late-stage studies or Phase III trials, are crucial to deciding if the immune response triggered by CoronaVac was sufficient to protect people from Covid-19.

Last week, Sinovac received approval from the Brazil National Health Surveillance Agency (Anvisa) to resume the Phase III trial of CoronaVac in the country.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology